{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:03:51Z","timestamp":1780031031761,"version":"3.53.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate endophthalmitis rates following intravitreal injection of aflibercept, comparing between vial preparation and prefilled syringe use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively collected data from ten ophthalmology departments in Israel. The number of intravitreal anti-VEGF injections administered in years 2022 and 2023 was recorded. Endophthalmitis rates in 2022 (vial use) and in 2023 (prefilled syringe use) were compared. Clinical details of endophthalmitis cases were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 2022, out of 119,904 intravitreal injections, 31,991 (27%) were aflibercept injections prepared from vials. In 2023, out of 128,306 intravitreal injections, 35,589 (28%) were aflibercept injections from prefilled syringes. Endophthalmitis rates were similar between vial preparation (1:1991) and prefilled syringe (1:2372) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.63). Notably, aflibercept injections exhibited significantly higher endophthalmitis rates compared to bevacizumab and ranibizumab combined, in both years (1:1999 vs. 1:5494 in 2022, and 1:2373 vs. 1:7132 in 2023, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01 for both).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the transit to prefilled aflibercept syringes, endophthalmitis rates following aflibercept injection did not decrease. Post-injection endophthalmitis rates were significantly higher with aflibercept compared to bevacizumab and ranibizumab, with both vial and prefilled syringe.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07285-2","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:29:43Z","timestamp":1780028983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Endophthalmitis rates following intravitreal injection of aflibercept using a prefilled syringe \u2013 a multicenter study"],"prefix":"10.1007","author":[{"given":"Daniel","family":"David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinah","family":"Zur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Biran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Braudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koby","family":"Brosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Moisseiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoreh","family":"Barak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalev","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Jaouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Pras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagay","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"7285_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/ICU.0000000000000143","volume":"26","author":"W Pearce","year":"2015","unstructured":"Pearce W, Hsu J, Yeh S (2015) Advances in drug delivery to the posterior segment. Curr Opin Ophthalmol 26:233\u2013239. https:\/\/doi.org\/10.1097\/ICU.0000000000000143","journal-title":"Curr Opin Ophthalmol"},{"key":"7285_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/archophthalmol.2010.19","volume":"128","author":"RJ Campbell","year":"2010","unstructured":"Campbell RJ (2010) Rapid Expansion of Intravitreal Drug Injection Procedures, 2000 to 2008. Arch Ophthalmol 128:359. https:\/\/doi.org\/10.1001\/archophthalmol.2010.19","journal-title":"Arch Ophthalmol"},{"key":"7285_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/IAE.0b013e3181a94f01","volume":"29","author":"GA Peyman","year":"2009","unstructured":"Peyman GA, Lad EM, Moshfeghi DM (2009) Intravitreal Injection of Therapeutic Agents. Retina 29:875\u2013912. https:\/\/doi.org\/10.1097\/IAE.0b013e3181a94f01","journal-title":"Retina"},{"key":"7285_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmology 116:57\u201365e5. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018","journal-title":"Ophthalmology"},{"key":"7285_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/IAE.0b013e318217d739","volume":"31","author":"J Googe","year":"2011","unstructured":"Googe J, Brucker AJ, Bressler NM et al (2011) Randomized Trial Evaluating Short-Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema After Focal\/Grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal Photocoagulation. Retina 31:1009\u20131027. https:\/\/doi.org\/10.1097\/IAE.0b013e318217d739","journal-title":"Retina"},{"key":"7285_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","volume":"169","author":"H Hoerauf","year":"2016","unstructured":"Hoerauf H, Feltgen N, Weiss C et al (2016) Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. Am J Ophthalmol 169:258\u2013267. https:\/\/doi.org\/10.1016\/j.ajo.2016.04.020","journal-title":"Am J Ophthalmol"},{"key":"7285_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193\u20131203. https:\/\/doi.org\/10.1056\/NEJMoa1414264","journal-title":"N Engl J Med"},{"key":"7285_CR8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897\u20131908. https:\/\/doi.org\/10.1056\/NEJMoa1102673","journal-title":"N Engl J Med"},{"key":"7285_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Campochiaro PA, Yau L et al (2012) Ranibizumab for Macular Edema Due to Retinal Vein Occlusions. Ophthalmology 119:802\u2013809. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.005","journal-title":"Ophthalmology"},{"key":"7285_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41433-023-02670-1","volume":"38","author":"GB Melo","year":"2024","unstructured":"Melo GB, Santos LA, Agra LL do M, et al (2024) Accuracy and residual volume of intravitreal injection syringes in administration of very small volumes. Eye 38:395\u2013396. https:\/\/doi.org\/10.1038\/s41433-023-02670-1","journal-title":"Eye"},{"key":"7285_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40942-022-00375-3","volume":"8","author":"J-M Guest","year":"2022","unstructured":"Guest J-M, Malbin B, Abrams G et al (2022) Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe. Int J Retina Vitreous 8:27. https:\/\/doi.org\/10.1186\/s40942-022-00375-3","journal-title":"Int J Retina Vitreous"},{"key":"7285_CR12","doi-asserted-by":"publisher","first-page":"18136","DOI":"10.1038\/s41598-022-23039-6","volume":"12","author":"VLS Dingerkus","year":"2022","unstructured":"Dingerkus VLS, Somfai GM, Kinzl S et al (2022) Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes. Sci Rep 12:18136. https:\/\/doi.org\/10.1038\/s41598-022-23039-6","journal-title":"Sci Rep"},{"key":"7285_CR13","unstructured":"Subhi Y, Kjer B, Munch IC (2016) Prefilled syringes for intravitreal injection reduce preparation time. Dan Med J 63(4):A5214."},{"key":"7285_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/02713683.2016.1276195","volume":"42","author":"E Moisseiev","year":"2017","unstructured":"Moisseiev E, Rudell J, Tieu EV, Yiu G (2017) Effect of Syringe Design on the Accuracy and Precision of Intravitreal Injections of Anti-VEGF Agents. Curr Eye Res 42:1059\u20131063. https:\/\/doi.org\/10.1080\/02713683.2016.1276195","journal-title":"Curr Eye Res"},{"key":"7285_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5301\/ejo.5000629","volume":"25","author":"E Souied","year":"2015","unstructured":"Souied E, Nghiem-Buffet S, Leteneux C et al (2015) Ranibizumab Prefilled Syringes: Benefits of Reduced Syringe Preparation Times and Less Complex Preparation Procedures. Eur J Ophthalmol 25:529\u2013534. https:\/\/doi.org\/10.5301\/ejo.5000629","journal-title":"Eur J Ophthalmol"},{"key":"7285_CR16","doi-asserted-by":"publisher","first-page":"22122","DOI":"10.1038\/s41598-020-79377-w","volume":"10","author":"M Morioka","year":"2020","unstructured":"Morioka M, Takamura Y, Nagai K et al (2020) Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics. Sci Rep 10:22122. https:\/\/doi.org\/10.1038\/s41598-020-79377-w","journal-title":"Sci Rep"},{"key":"7285_CR17","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","volume":"31","author":"CA McCannel","year":"2011","unstructured":"McCannel CA (2011) Meta-Analysis of Endophthalmitis After Intravitreal Injection of Anti\u2013Vascular Endothelial Growth Factor Agents. Retina 31:654\u2013661. https:\/\/doi.org\/10.1097\/IAE.0b013e31820a67e4","journal-title":"Retina"},{"key":"7285_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ophtha.2017.07.005","volume":"125","author":"V Daien","year":"2018","unstructured":"Daien V, Nguyen V, Essex RW et al (2018) Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. Ophthalmology 125:66\u201374. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.005","journal-title":"Ophthalmology"},{"key":"7285_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/OPTH.S169044","volume":"13","author":"TM Sassalos","year":"2019","unstructured":"Sassalos TM, Paulus YM (2019) Prefilled syringes for intravitreal drug delivery. Clin Ophthalmol 13:701\u2013706. https:\/\/doi.org\/10.2147\/OPTH.S169044","journal-title":"Clin Ophthalmol"},{"key":"7285_CR20","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41433-018-0138-8","volume":"32","author":"F Menchini","year":"2018","unstructured":"Menchini F, Toneatto G, Miele A et al (2018) Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review. Eye 32:1423\u20131431. https:\/\/doi.org\/10.1038\/s41433-018-0138-8","journal-title":"Eye"},{"key":"7285_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000518236","volume":"245","author":"M Finkelstein","year":"2022","unstructured":"Finkelstein M, Katz G, Zur D et al (2022) The Effect of Syringe-Filling Technique on the Risk for Endophthalmitis after Intravitreal Injection of Anti-VEGF Agents. Ophthalmologica 245:34\u201340. https:\/\/doi.org\/10.1159\/000518236","journal-title":"Ophthalmologica"},{"key":"7285_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","volume":"199","author":"PP Storey","year":"2019","unstructured":"Storey PP, Tauqeer Z, Yonekawa Y et al (2019) The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab. Am J Ophthalmol 199:200\u2013208. https:\/\/doi.org\/10.1016\/j.ajo.2018.11.023","journal-title":"Am J Ophthalmol"},{"key":"7285_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/24741264231159011","volume":"7","author":"HL Feng","year":"2023","unstructured":"Feng HL, Abdelwahab S, Imam N et al (2023) Reduced Incidence of Intravitreal Injection\u2013Related Endophthalmitis with Prefilled Syringes. J Vitreoretin Dis 7:305\u2013309. https:\/\/doi.org\/10.1177\/24741264231159011","journal-title":"J Vitreoretin Dis"},{"key":"7285_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2147\/OPTH.S393519","volume":"17","author":"U Schmidt-Ott","year":"2023","unstructured":"Schmidt-Ott U, Fitzpatrick S, Hasanbasic Z et al (2023) Reported Rates of Intraocular Inflammation with Intravitreal Aflibercept Administered via Pre-Filled Syringe or from Vials in Clinical Practice Between 2012 and 2022. Clin Ophthalmol 17:385\u2013390. https:\/\/doi.org\/10.2147\/OPTH.S393519","journal-title":"Clin Ophthalmol"},{"key":"7285_CR25","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.3390\/jcm14072491","volume":"14","author":"M Morioka","year":"2025","unstructured":"Morioka M, Takamura Y, Yoshida S et al (2025) Comparison of Endophthalmitis Rates Between Prefilled Syringes and Standard Vials in Aflibercept Intravitreal Injections: A Retrospective Study in Japan. J Clin Med 14:2491. https:\/\/doi.org\/10.3390\/jcm14072491","journal-title":"J Clin Med"},{"key":"7285_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/OPTH.S76406","volume":"9","author":"K Vaziri","year":"2015","unstructured":"Vaziri K, Schwartz SG, Kishor K, Flynn HW (2015) Endophthalmitis: state of the art. Clin Ophthalmol 9:95\u2013108. https:\/\/doi.org\/10.2147\/OPTH.S76406","journal-title":"Clin Ophthalmol"},{"key":"7285_CR27","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E et al (2018) Clinical pharmacology of intravitreal anti-VEGF drugs. Eye 32:1010\u20131020. https:\/\/doi.org\/10.1038\/s41433-018-0021-7","journal-title":"Eye"},{"issue":"2","key":"7285_CR28","doi-asserted-by":"publisher","first-page":"e00723","DOI":"10.1002\/prp2.723","volume":"9","author":"ML Formica","year":"2021","unstructured":"Formica ML, Awde Alfonso HG, Palma SD (2021) Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology. Pharmacol Res Perspect 9(2):e00723. https:\/\/doi.org\/10.1002\/prp2.723","journal-title":"Pharmacol Res Perspect"},{"key":"7285_CR29","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.curtheres.2024.100742","volume":"100","author":"HM Kim","year":"2024","unstructured":"Kim HM, Woo SJ (2024) Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs. Curr Ther Res 100:100742. https:\/\/doi.org\/10.1016\/j.curtheres.2024.100742","journal-title":"Curr Ther Res"},{"key":"7285_CR30","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1097\/IAE.0000000000003232","volume":"41","author":"JW Hinkle","year":"2021","unstructured":"Hinkle JW, Hsu J (2021) The Relationship Between Stopper Position and Injection Volume in Ranibizumab and Aflibercept Prefilled Syringes. Retina 41:2510\u20132514. https:\/\/doi.org\/10.1097\/IAE.0000000000003232","journal-title":"Retina"},{"issue":"1","key":"7285_CR31","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/aos.15719","volume":"102","author":"M Issa","year":"2024","unstructured":"Issa M, Balas M, Popovic MM, Lytvyn Y, Kertes PJ, Muni RH (2024) Pars plana vitrectomy versus intravitreal antibiotics for endophthalmitis management following intravitreal anti-VEGF agents: A meta-analysis. Acta Ophthalmol 102(1):e11\u2013e21. https:\/\/doi.org\/10.1111\/aos.15719","journal-title":"Acta Ophthalmol"},{"key":"7285_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/24741264231191339","volume":"7","author":"AM Louis","year":"2023","unstructured":"Louis AM, Ali AM, Patel SB et al (2023) Impact of Prefilled Syringes and Masking on Postintravitreal Injection Endophthalmitis. J Vitreoretin Dis 7:382\u2013388. https:\/\/doi.org\/10.1177\/24741264231191339","journal-title":"J Vitreoretin Dis"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07285-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07285-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07285-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:29:45Z","timestamp":1780028985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07285-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":32,"alternative-id":["7285"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07285-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Sheba institutional review board (SMC-D-0435-23) and adheres to the tenets of the Declaration of Helsinki. Obtaining consent to participate was waived by the Sheba institutional review board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}